Former Chief Financial Officer · Viking Therapeutics, Inc. (VKTX)

Michael Morneau

A named executive officer of Viking Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$619,564

Salary $285,333Stock awards $69,750

FY2017: $452,860

3rd of 3 named executive officers at Viking Therapeutics by FY2018 total.

3 named officers on file for Viking Therapeutics, FY2018

Michael Morneau’s pay file — $29

  • 2 fiscal years of pay, line by line
  • VKTX’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Viking Therapeutics’s whole pay program stands against its peers

  • Viking Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VKTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 5, 2019 (DEF 14A).

Free

Get Michael Morneau’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Michael Morneau compensation by year

Viking Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Viking Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018
Salary$300,000$285,333
Bonus$0$0
Stock awards$0$69,750
Option awards$100,360$174,481
Non-equity incentive$52,500$90,000
Pension and deferred compensation$0$0
All other$0$0
Total$452,860$619,564

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Viking Therapeutics, Inc. DEF 14A filed April 5, 2019, accession 0001564590-19-010928, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Viking Therapeutics, Inc. filed document, accession 0001564590-19-010928. Every figure is read from that document and cited to the page and table it appears in. Filed April 5, 2019.

$453K
$620K
FY17
FY18
SalaryNon-equity incentiveStock awardsOption awards

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
PSU15,000$69,750—
Option52,500—$4.65
Option71,250—$1.23
Option20,000—$2.15

Per the Outstanding Equity Awards at Fiscal Year-End table in Viking Therapeutics, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Viking Therapeutics’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Brian LianChief Executive Officer$1,403,283
Hiroko MasamuneChief Development Officer$992,924
Michael Morneau · this pageFormer Chief Financial Officer$619,564

The full Viking Therapeutics compensation record

free company brief

This page is one person within Viking Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Viking Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael Morneau's compensation dossier · One-time report. No refunds.